Halliburton Q2 Adjusted Net Income, Revenue Advance -- Shares Decline Pre-Bell-March 2024-www.financetom.com

Halliburton Q2 Adjusted Net Income, Revenue Advance -- Shares Decline Pre-Bell

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Halliburton Q2 Adjusted Net Income, Revenue Advance -- Shares Decline Pre-Bell

Jul 19, 2024 4:45 AM

07:28 AM EDT, 07/19/2024 (MT Newswires) -- Halliburton ( HAL ) reported Q2 adjusted net income Friday of $0.80 per diluted share, up from $0.77 a year earlier.

Analysts polled by Capital IQ expected $0.80.

Revenue for the quarter ended June 30 was $5.83 billion, up from $5.80 billion a year earlier.

Analysts surveyed by Capital IQ expected $5.95 billion.

Shares of the oil services company were down more than 2% in recent Friday premarket activity.

Price: 35.57, Change: -0.87, Percent Change: -2.39

Previous page： York Space Systems Acquires Orbion Space Technology, Further Strengthening Supply Chain with Flight-Proven Spacecraft Capability Next page： Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

York Space Systems Acquires Orbion Space Technology, Further Strengthening Supply Chain with Flight-Proven Spacecraft Capability

Mar 12, 2026

DENVER--(BUSINESS WIRE)-- York Space Systems ( YSS ) , a leading, US-based national defense and commercial prime providing a comprehensive suite of mission-critical solutions, today announced it has acquired Orbion Space Technology (Orbion), a Michigan-based manufacturer of flight-proven electric propulsion systems. The acquisition strengthens York’s integrated space ecosystem and directly supports the strategy the company outlined at the time of...

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

Mar 12, 2026

Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors PARIS & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. ( KZR ) , a clinical-stage biotechnology company developing novel small...

Kraken Robotics Closes $402.5 Million Public Offering of Subscription Receipts

Mar 12, 2026

08:59 AM EDT, 03/12/2026 (MT Newswires) -- Kraken Robotics ( KRKNF ) said Thursday that its subscription receipts offering raised $402.5 million. The company issued 47.4 million receipts at $8.50 each, which included the full exercise of the over-allotment option. Proceeds will partially fund the cash portion for the $615 million acquisition of Covelya Group, a provider of mission-critical underwater...

Natera Launches Zenith Genomics for Rare Disease Diagnosis

Mar 12, 2026

08:59 AM EDT, 03/12/2026 (MT Newswires) -- Natera ( NTRA ) said Thursday it has commercially launched its Zenith genomics sequencing assay to improve detection of rare diseases. Zenith genomics offers detection of typically hard to detect features like tandem repeat expansions by using long-read sequencing confirmation for diagnostic clarity, according to the company. Natera ( NTRA ) said genome...